Can low-dose immunotherapy work when standard doses are unaffordable?
At @KtmCancerCenter, we studied low-dose nivolumab (20–40 mg), finding encouraging real-world outcomes with manageable toxicity.
Possibly Nepal’s first indexed-journal study on immunotherapy.
#CancerResearch
At @KtmCancerCenter, we studied low-dose nivolumab (20–40 mg), finding encouraging real-world outcomes with manageable toxicity.
Possibly Nepal’s first indexed-journal study on immunotherapy.
#CancerResearch